Document is current
Any future updates will be listed below
-
Authors
Passariello, Margherita
Manna, Lorenzo
Rapuano Lembo, Rosa https://orcid.org/0009-0007-4810-8255
Yoshioka, Asami
Inoue, Toshikazu
Kajiwara, Kentaro
Hashimoto, Shu‑ichi
Nakamura, Koji https://orcid.org/0009-0007-7761-3795
De Lorenzo, Claudia https://orcid.org/0000-0002-6195-5631
-
Funding
Funding for this research was provided by:
Partial support by Chiome Bioscience Inc.
- License Information
-
More Information
Article History
Received: 23 September 2024
Revised: 23 December 2024
Accepted: 27 January 2025
First Online: 10 February 2025
Competing interests
: The authors declare that the patent (PCT/JP2023/024487) relative to the novel tri-specific tribodies was recently filed, and the authors AY, TI, KK, SH, and KN are employees of Chiome Bioscience Inc.
: All methods were performed in accordance with the relevant guidelines and regulations. No studies on human participants were carried out. All animal experiments in this study were approved and conducted in accordance with the Institutional Animal Care and Use Committee guidelines of Chiome Bioscience Inc. (Shibuya-Ku, Tokyo Japan). The name of committee is Chiome Bioscience Animal Experimentation Committee; Registration number: A2024-004. Date of approval: March 19, 2024 Study title: Efficacy evaluation of a novel trispecific Tribody molecule in a subcutaneous tumor model of human cancer cells expressing 5T4 on the cell surface and human PBMC mixed cell mouse model or human PBMC engraftment model in subcutaneous transplantation of cancer cells in mice.
